# Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose

> **NCT01823536** · PHASE4 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 465 (actual)

## Conditions studied

- Meningococcal Disease

## Interventions

- **BIOLOGICAL:** Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine

## Key facts

- **NCT ID:** NCT01823536
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2013-10
- **Final completion:** 2014-06
- **Target enrollment:** 465 (ACTUAL)
- **Last updated:** 2014-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01823536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01823536, "Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01823536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*